The most common grade 3 or 4 adverse events were low neutrophil count ( 15 [ 11 % ] preoperatively in the chemotherapy alone group vs six [ 4 % ] in the chemotherapy plus cetuximab group ; four [ 4 % ] vs eight [ 8 % ] postoperatively ) , embolic events ( six [ 4 % ] vs eight [ 6 % ] preoperatively ; two [ 2 % ] vs three [ 3 % ] postoperatively ) , peripheral neuropathy ( six [ 4 % ] vs one [ 1 % ] preoperatively ; two [ 2 % ] vs four [ 4 % ] postoperatively ) , nausea or vomiting ( four [ 3 % ] vs six [ 4 % ] preoperatively ; four [ 4 % ] vs two [ 2 % ] postoperatively ) , and skin rash ( two [ 1 % ] vs 21 [ 15 % ] preoperatively ; 0 vs eight [ 8 % ] postoperatively ) .